Published in Nature, a groundbreaking study from McMaster University and Espervita Therapeutics reveals that inhibiting ATP citrate lyase (ACLY), essential for fatty acid synthesis, remodels the liver tumor microenvironment. This reprogramming reduces lipid accumulation and uniquely stimulates B cell infiltration, generating a potent antitumor immune response. The novel small molecule EVT0185 demonstrated efficacy across multiple mouse models of metabolic-associated steatohepatitis-driven hepatocellular carcinoma (MASH-HCC), highlighting new avenues for liver cancer immunotherapy.